申请人:Astellas Pharma Inc.
公开号:US08263607B2
公开(公告)日:2012-09-11
Provided is a compound useful as an N-type Ca2+ channel blocker. As a result of intensive studies of compounds having an action of blocking N-type Ca2+ channels, the present inventors found that a tetrahydroisoquinoline compound of the present invention having a substituent at the 1-position has an action of blocking the N-type Ca2+ channels, an antinociceptive pain action, an antineuropathic pain action, an abdominal pain-inhibitory action and an opioid-induced constipation-improving action, and the present invention has been completed based on these findings. The compound of the present invention can be used as a pharmaceutical composition for preventing and/or treating various pains such as neuropathic pain and nociceptive pain, headaches such as migraine and cluster headache, central nervous system diseases such as anxiety, depression, epilepsy, cerebral stroke and restless legs syndrome, abdominal symptoms such as abdominal pain and abdominal distension, stool abnormalities such as diarrhea and constipation, digestive system diseases such as irritable bowel syndrome, urinary system diseases such as overactive bladder and interstitial cystitis, etc.
提供的是一种作为N型Ca2+通道阻滞剂有用的化合物。由于对具有阻断N型Ca2+通道作用的化合物进行了深入研究,本发明人发现,本发明的四氢异喹啉化合物在1位具有取代基,具有阻断N型Ca2+通道、抗痛觉疼痛作用、抗神经痛作用、抑制腹痛作用和改善阿片类药物引起的便秘作用,基于这些发现完成了本发明。本发明的化合物可用作预防和/或治疗各种疼痛,如神经痛和伤害性疼痛、头痛,如偏头痛和集群头痛、中枢神经系统疾病,如焦虑、抑郁、癫痫、脑卒中和不宁腿综合征、腹部症状,如腹痛和腹胀、大便异常,如腹泻和便秘、消化系统疾病,如肠易激综合征、泌尿系统疾病,如过度活动膀胱和间质性膀胱炎等的药物组成物。